Skip to main navigation Skip to search Skip to main content

Zoledronate as effective treatment for minimal trauma fractures in a child with STAT3 deficiency and osteonecrosis of the hip

  • Aidé Tamara Staines Boone
  • , Julio César Alcántara-Montiel
  • , Luz María Sánchez-Sánchez
  • , Marina Arce-Cano
  • , Jorge García-Campos
  • , Saúl Oswaldo Lugo Reyes

Research output: Contribution to journal › Article › peer-review

Abstract

Signal transducer and activator of transcription 3 (STAT3) deficiency is a primary immunodeficiency characterized by eczema, complicated recurrent infections, elevated serum immunoglobulin E (IgE), osteopenia, and minimal trauma fractures. Zoledronic acid (ZA) is a long-acting bisphosphonate that has been successfully used in children with secondary osteoporosis and osteogenesis imperfecta. We describe the case of a 7-year-old male with STAT3 deficiency and minimal trauma fractures, who also developed osteonecrosis of the hip. He responded well to intravenous ZA every 6 months for 18 months. Three years later, he walks independently and unaided, and has not suffered any other fractures. Although more studies are needed, ZA might help reduce minimal trauma fractures in patients with STAT3 deficiency.

Original languageEnglish (US)
Pages (from-to)2054-2057
Number of pages4
JournalPediatric Blood and Cancer
Volume63
Issue number11
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Keywords

  • arthroplasty
  • avascular necrosis of the hip
  • bisphosphonate
  • hyper-IgE syndrome
  • job syndrome
  • osteonecrosis of the femoral head
  • osteopenia
  • primary immunodeficiency
  • STAT3 deficiency
  • zoledronic acid

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Zoledronate as effective treatment for minimal trauma fractures in a child with STAT3 deficiency and osteonecrosis of the hip'. Together they form a unique fingerprint.

Cite this